Abstract
The purpose of this work was to analyse the ability of p53 and thymidilate synthase (TS) primary tumour expression to retrospectively predict clinical response to chemotherapy and long-term prognosis in patients with advanced colorectal cancers homogeneously treated by methotrexate (MTX)-modulated–5-fluorouracil (5-FU-FA). A total of 108 advanced colorectal cancer patients entered the present retrospective study. Immunohistochemical p53 (pAb 1801 mAb) and TS (TS106 mAb) expression on formalin-fixed paraffin-embedded primary tumour specimens was related to probability of clinical response to chemotherapy, time to progression and overall survival. p53 was expressed in 53/108 (49%) tumours, while 54/108 (50%) showed TS immunostaining. No relationship was demonstrated between p53 positivity and clinical response to chemotherapy (objective response (OR): 20% vs 23%, in p53+ and p53– cases respectively) or overall survival. Percent of OR was significantly higher in TS-negative with respect to TS-positive tumours (30% vs 15% respectively; P< 0.04); simultaneous analysis of TS and p53 indicated 7% OR for p53-positive/TS-positive tumours vs 46% for p53-positive/TS-negative tumours (P< 0.03). Logistic regression analysis confirmed a significant association between TS tumour status and clinical response to chemotherapy (hazard ratio (HR): 2.91; 95% confidence interval (CI) 8.34–1.01; two-sided P< 0.05). A multivariate analysis of overall survival showed that only a small number of metastatic sites was statistically relevant (HR 1.89; 95% CI 2.85–1.26; two-sided P< 0.03). Our study suggests that immunohistochemical expression of p53 and TS could assist the clinician in predicting response of colorectal cancer patients to modulated MTX-5-FU therapy. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
American Joint Committee on Cancer (1988) Manual for Staging of Cancer. 3rd edn, p. 7. Lippincott: Philadelphia
Bathavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI and Suthar TP (1997) Coexpression of Bcl-2, c-myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40: 785–790
Bosari S and Viale G (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86: 681–687
Boyle P (1997) Global burden of cancer. Lancet 349: 23–26
Bulleco C, Guillem JG, Kemeney N, Huang Y, Klimistra D and Berger MF (1996) p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14: 2696–2701
Chin KV, Ueda K, Pastran I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by RAS and p53. Science 255: 459–462
Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA and Yeh GC (1990) Induction of thymidilate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136–143
Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA and Elwood BC (1991) Autoregulation of human thymidilate messenger RNA translation by thymidilate synthase. Proc Natl Acad Sci USA 88: 8977–8981
Cook A and Milner J (1990) Evidence of allosteric variants for wild type p53, a tumour suppressor protein. Br J Cancer 61: 548–562
Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I and Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal-cancer-methodological studies. Eur. J. Cancer 33: 2278–2282
Findlay MPN, Cunningham D, Morgan G and Clinton S (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy. Br J Cancer 75: 903–909
Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878
Hermeking H and Heick D (1994) Mediation of c-myc-induced apoptosis by p53. Science 265: 2091–2093
Isacoff WH and Borud K (1997) Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg 21: 748–762
Johnston PG, Liang CM, Henry S, Chabner BA and Allegra C (1991) Production and characterization of monoclonal antibodies that localize human thymidilate synthase in the cytoplasm of human cells and tissue. Cancer Res 51: 6668–6676
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N and Drake JC (1994) The role of thymidilate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647
Johnston PG, Lenz HJ, Leichman CG, Danenberg K, Allegra C and Danenberg PV (1995) Thymidilate synthase gene and protein expression correlate and are associated with response to 5-Fluorouracil in human colorectal and gastric cancer. Cancer Res 55: 1407–1412
Johnston PG, Mick R, Recant W, Behan KA, Dolan ME and Ratain MJ (1997) Thymidilate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89: 308–313
Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R and Butzer U (1997) Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion. Cancer Letter 118: 29–35
Larsson PA, Carlsson G, Gustavsson B and Spears PC (1996) Thymidilate synthase in advanced gastrointestinal and breast cancers. Acta Oncologica 35: 469–472
Lee Y, Chen Y, Chang LS and Johnson LF (1997) Inhibition of mouse thymidilate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 234: 270–276
Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J and Groshen S (1997) Quantitation of intratumoral thymidilate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223–3229
Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger T, Banerijee D, Bertino JR, Groshen S, Leichman LP and Leichman CG (1998) p53 point mutations and Thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res 4: 1243–1250
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE and Fisher DE (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807–810
Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT and Bianco A (1991) Advanced colorectal carcinoma. Am J Clin Oncol 14: 211–217
Machover D (1997) A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179–1187
Manne U, Myers RB, Moron C, Poczatek RB, Dillard S and Weiss H (1997) Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74: 346–358
Merchant AK, Loney TL and Maybaum J (1996) Expression of wild-type p53 stimulates an increase in both Bax and Bcl-x(L) protein content in HT29 cells. Oncogene 13: 2631–2637
Mueller H and Eppenberger U (1996) The dual role of mutant p53 protein in chemosensitivity of human cancer. Anticancer Res 16: 3845–3848
Navalgund LG, Rossann C, Muench AJ and Johnson LF (1980) Cell cycle regulation of thymidilate synthase gene expression in culture mouse fibroblasts. J Biol Chem 255: 7386–7390
Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A and Perez J (1996) p53 and PCNA expression in advanced colorectal cancer. Response to chemotherapy and long-term prognosis. Int J Cancer 69: 437–441
Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake JC, Glennon MC and Allegra CJ (1995) Increased thymidilate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 71: 1151–1157
Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA and Trihia H (1997) Prognostic importance of thymidilate synthase expression in early breast cancer. J Clin Oncol 15: 1923–1931
Peters GJ, Van Der Wilt CL, Van Groeningen CJ, Meijer S, Smid K and Pinedo HM (1994) Thymidilate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil. J Clin Oncol 12: 2035–2042
Peters GJ, Van Der Wilt CL, Van Triest B, Codacci-Pisanelli G, Johnston PG and Van Groeningen CJ (1995) Thymidylate synthase and drug resistance. Eur J Cancer 31(7): 1299–1305
SEER Cancer Statistics Review 1973–1993 preliminary edition. Colorectal cancer incidence. (1997). J Natl. Cancer Inst 89: 416
Simes RJ and Zelen M (1985) Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's prime. J Clin Oncol 3: 1418–1431
Slebos RJC, Baas IO, Clement M, Polak M, Mulder JW and Van Den Berg FM (1996) Clinical and pathological associations with p53 tumor-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 74: 165–171
Smith DR, Ji CY and Goh HS (1996) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74: 216–223
Spears C (1995) Clinical resistance to antimetabolites. Haematol Oncol Clin North Am 9: 397–413
Spears CP, Shahanian AH and Moran RG (1982) In vivo kinetics of thymidilate synthase inhibition of 5-fluorouracil-sensitive and resistant murine colon adenocacarcinomas. Cancer Res 42: 450–456
Yang B, Eshleman JR, Berger NA and Markowitz SD (1996) Wild-type p53 potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649–1657
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Paradiso, A., Simone, G., Petroni, S. et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82, 560–567 (2000). https://doi.org/10.1054/bjoc.1999.0964
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0964
Keywords
This article is cited by
-
Prognostic value of neutrophil-to-lymphocyte ratio in metastatic colorectal cancer ⁎
Oncology and Translational Medicine (2016)
-
Thymidylate synthase expression and p21WAF1/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy
Cellular Oncology (2014)
-
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer
Cancer Chemotherapy and Pharmacology (2012)
-
The Colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information
BMC Cancer (2010)
-
Prognostic and Predictive Value of Thymidylate Synthase Expression in Colon Cancer
Digestive Diseases and Sciences (2008)